Patients taking semaglutide, the active ingredient in Ozempic, were less likely to develop Alzheimer’s. Randomized clinical trials are needed to pin down the exact cause of this difference in risk.

CHICAGO, June 21, 2025 /PRNewswire/ -- Today, a new analysis demonstrates the vascular benefits of semaglutide in patients with peripheral artery disease (PAD) and type 2 diabetes, including ...

Three GLP-1s, liraglutide, semaglutide and dulaglutide, have now been approved to reduce the risks of cardiovascular disease. Several studies indicate GLP-1s may have even farther-ranging benefits.

A bipartisan group of congressional lawmakers is calling on the Trump administration to address the continued sale of illicit, compounded GLP-1 products, warning that consumers may be accessing the… ...

Through the power of his veto pen, Gov. Ron DeSantis has the final say on most decisions made by the Legislature. If he agrees with them, as he has dozens of times in recent weeks, then their ...

In distinct clinical human studies, Lexaria has now demonstrated clear reductions in AEs utilizing oral DehydraTECH versions of all three of the major GLP-1 drugs sold in the world today ...

ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care ...

In the context of the global obesity epidemic, the FDA approved several glucagon-like peptide-1 (GLP-1) receptor agonists (GPL-1RAs), such as liraglutide (Saxenda) and semaglutide (Ozempic, Wegovy ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing neovascular age-related macular degeneration (nAMD) in older patients with ...

For months, third graders at Crooked Lake Elementary in Andover, Minnesota have been trading letters with pen pals a few generations older. On Friday, they finally met face-to-face.